fda compounding semaglutide news september 2025 A network meta-analysis backed weight-loss benefits with several GLP-1 receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio September 8, 2025: FDA launches

Tesamorelin peptide therapy consultations at Florida Surgery & Weight Loss Center are provided by Karla K

Zepbound (tirzepatide) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist-the first and only approved treatment activating both incretin hormone receptors

The scale moves slowly

By slowing gastric emptying and altering gut motility, semaglutide can affect the balance of the gut microbiome, potentially creating a favorable environment for yeast overgrowth

They followed this with a metaanalysis, which pools the results of multiple studies to estimate an overall effect

New generation GLP-1 analogues like liraglutide, semaglutide, and dulaglutide have shown cardiovascular pluses and proven useful in weight control interventions